Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Internal Medicine | Nursing | Pharmacy | Psychiatry | Journal

Back to Journal Articles

Antipsychotic Maintenance Rx Aids Schizophrenia Patients

Last Updated: May 03, 2012.

 

But benefits of antipsychotic maintenance therapy need to be weighed against risk of side effects

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Maintenance therapy with antipsychotic drugs is associated with a reduction in the relapse rate in schizophrenia, but benefits must be weighed against risks of adverse side effects, according to a review published online May 3 in The Lancet.

THURSDAY, May 3 (HealthDay News) -- Maintenance therapy with antipsychotic drugs is associated with a reduction in the relapse rate in schizophrenia, but benefits must be weighed against risks of adverse side effects, according to a review published online May 3 in The Lancet.

Stefan Leucht, M.D., from Technische Universität München in Munich, Germany, and colleagues reviewed the literature to assess the correlation between antipsychotic drugs and outcomes in schizophrenia. A total of 116 reports from 65 trials were identified, involving 6,493 patients. Relapse between seven and 12 months was the primary outcome assessed.

The researchers found that, compared with placebo treatment, relapse rates were significantly reduced at one year with antipsychotic drugs (27 versus 64 percent; risk ratio [RR], 0.40) and fewer patients given antipsychotic drugs were readmitted (10 versus 26 percent). Of the relapsed patients, less than a third had to be readmitted. From limited data there was a suggestion of better quality of life and fewer aggressive acts with antipsychotic drugs. Compared with placebo-treated patients, more patients treated with antipsychotic drugs had movement disorders, gained weight, and experienced sedation. There was considerable heterogeneity in the effect size. There was no correlation between the number of episodes, first-generation or second-generation drugs, and allocation concealment method with relapse risk. Relapse rate was reduced more with depot preparations (RR, 0.31) than oral drugs (RR, 0.46), with depot haloperidol and fluphenazine having the greatest effects (RR, 0.14 and 0.23, respectively).

"Maintenance treatment with antipsychotic drugs benefits patients with schizophrenia. The advantages of these drugs must be weighed against their side-effects," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Problem Behavior Up Among Children Born Post-Term Next: New Guidelines for Aneurysmal Subarachnoid Bleeds Issued

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.